DrugPatentWatch Database Preview
Sorafenib tosylate - Generic Drug Details
What are the generic sources for sorafenib tosylate and what is the scope of sorafenib tosylate freedom to operate?
Sorafenib tosylate
is the generic ingredient in one branded drug marketed by Bayer Hlthcare and is included in one NDA. There are eight patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.Sorafenib tosylate has two hundred and twelve patent family members in fifty-six countries.
There are thirteen drug master file entries for sorafenib tosylate. One supplier is listed for this compound.
Summary for sorafenib tosylate
| International Patents: | 212 |
| US Patents: | 8 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Drug Master File Entries: | 13 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 85 |
| Clinical Trials: | 158 |
| Patent Applications: | 6 |
| Formulation / Manufacturing: | see details |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for sorafenib tosylate |
| DailyMed Link: | sorafenib tosylate at DailyMed |
Pharmacology for sorafenib tosylate
| Drug Class | Kinase Inhibitor |
| Mechanism of Action | Protein Kinase Inhibitors |
Synonyms for sorafenib tosylate
| 1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(4-((2-(methylcarbamoyl)pyridin-4-yl)oxy)phenyl)urea mono(4-methylbenzenesulfonate) |
| 1-(4-chloro-3-(Trifluoromethyl)phenyl)-3-(4-((2-(methylcarbamoyl)pyridin-4-yl)oxy)phenyl)urea mono(4-methylbenzenesulfonic acid) |
| 1-(4-chloro-3-(Trifluoromethyl)phenyl)-3-(4-((2-(methylcarbamoyl)pyridin-4-yl)oxy)phenyl)urea mono(4-methylbenzenesulphonate) |
| 1-(4-chloro-3-(Trifluoromethyl)phenyl)-3-(4-((2-(methylcarbamoyl)pyridin-4-yl)oxy)phenyl)urea mono(4-methylbenzenesulphonic acid) |
| 2-Pyridinecarboxamide, 4-(4-((((4-chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-, mono(4-methylbenzenesulfonate) |
| 207S591 |
| 3(S),10(R)-OH-octadeca-6-trans-4,12-cis-trienoate |
| 3(S),10(R)-OH-Octadeca-6-trans-4,12-cis-trienoic acid |
| 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-N-methylpicolinamide 4-methylbenzenesulfonate |
| 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-N-methylpicolinamide tosylate |
| 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-N2-methylpyridine-2-carboxamide mono (4-methylbenzenesulfonate) |
| 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide 4-methylbenzenesulfonate |
| 4-[4-[[[4-chloro-3-(trifluoromethyl)anilino]-oxomethyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; 4-methylbenzenesulfonic acid |
| 4-[4-[[4-chloranyl-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide; 4-methylbenzenesulfonic acid |
| 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide; 4-methylbenzenesulfonic acid |
| 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide;4-methylbenzenesulfonic acid |
| 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)-amino]phenoxy}-N-methylpyridine-2-carboxamide tosylate |
| 4-{4-[({[4-Chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-N -methylpyridine-2-carboxamide tosylate |
| 4-{4-[({[4-Chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-N-methylpyridine-2-carboxamide tosylate |
| 4-{4-[3-(4-Chloro-3-trifluoromethyl-phenyl)-ureido]-phenoxy} -pyridine-2-carboxylic acid methylamide-4-methylbenzenesulfonate |
| 4-{4-[3-(4-Cl-3-trifluoromethyl-phenyl)-ureido]-phenoxy}-pyridine-2-carboxylic acid methylamide 4-methylbenzenesulfonate |
| 4-methylbenzolsulfons |
| 475207-59-1 |
| 5T62Q3B36J |
| A20368 |
| A819449 |
| AB0044027 |
| ABP000935 |
| AC-6799 |
| AC1L8QVY |
| AC1Q5GRN |
| AK162385 |
| AKOS015924650 |
| AKOS027469919 |
| AM20090612 |
| AOB87366 |
| AT-17079 |
| BAY 43-9006 mono-p-tosylate |
| BAY 43-9006 tosylate |
| BAY 54-9085 |
| BAY 54-9085Sorafenib tosylATE |
| BAY 54-9085Sorafenib tosylic acid |
| BAY-54-9085 |
| BAY43-9006 mono-p-tosylate |
| BCP0726000112 |
| C28H24ClF3N4O6S |
| CAS-475207-59-1 |
| CCG-208000 |
| CHEBI:50928 |
| CHEMBL1200485 |
| CS-0164 |
| D06272 |
| DSSTox_CID_27817 |
| DSSTox_GSID_47839 |
| DSSTox_RID_82581 |
| DTXSID9047839 |
| FT-0650737 |
| FT-0698449 |
| HE072572 |
| HE344612 |
| HMS2219E08 |
| HMS3654I09 |
| HY-10201A |
| IVDHYUQIDRJSTI-UHFFFAOYSA-N |
| KS-000006NB |
| LS-186598 |
| MFCD08235032 |
| MLS002415564 |
| MolPort-006-705-989 |
| NCGC00167488-01 |
| NCGC00167488-08 |
| ND-0228 |
| Nexavar (TN) |
| Nexavar(R) |
| NSC-724772 |
| NSC724772 |
| para-toluene sulfonate sorafenib tosylate |
| PubChem22488 |
| Q-1222 |
| Q-201729 |
| Q812 |
| RL03773 |
| S-8502 |
| s1040 |
| SMR001339079 |
| Sorafenib - Nexavar |
| Sorafenib (BAY-43-9006) |
| Sorafenib (Tosylate) |
| Sorafenib tosilate |
| Sorafenib tosilate (JAN) |
| Sorafenib tosilic acid |
| Sorafenib tosylate (USAN) |
| Sorafenib tosylate [USAN] |
| Sorafenib Tosylate(Bay 43-9006)/ |
| Sorafenib TsOH salt |
| Sorafenib, p-Toluenesulfonate salt |
| SORAFENIB; TOLUENESULFONIC ACID |
| SR-00000000529 |
| SR-00000000529-5 |
| ST24049296 |
| Tox21_112489 |
| Tox21_112489_1 |
| UNII-5T62Q3B36J |
US Patents and Regulatory Information for sorafenib tosylate
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bayer Hlthcare | NEXAVAR | sorafenib tosylate | TABLET;ORAL | 021923-001 | Dec 20, 2005 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | |||
| Bayer Hlthcare | NEXAVAR | sorafenib tosylate | TABLET;ORAL | 021923-001 | Dec 20, 2005 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | |||
| Bayer Hlthcare | NEXAVAR | sorafenib tosylate | TABLET;ORAL | 021923-001 | Dec 20, 2005 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Bayer Hlthcare | NEXAVAR | sorafenib tosylate | TABLET;ORAL | 021923-001 | Dec 20, 2005 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Bayer Hlthcare | NEXAVAR | sorafenib tosylate | TABLET;ORAL | 021923-001 | Dec 20, 2005 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | |||
| Bayer Hlthcare | NEXAVAR | sorafenib tosylate | TABLET;ORAL | 021923-001 | Dec 20, 2005 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | Y | ➤ Try a Free Trial | ||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
International Patents for sorafenib tosylate
| Country | Document Number | Estimated Expiration |
|---|---|---|
| South Korea | 20070020158 | ➤ Try a Free Trial |
| Hong Kong | 1114605 | ➤ Try a Free Trial |
| Norway | 321059 | ➤ Try a Free Trial |
| Hong Kong | 1062440 | ➤ Try a Free Trial |
| Austria | 460398 | ➤ Try a Free Trial |
| European Patent Office | 1158985 | ➤ Try a Free Trial |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for sorafenib tosylate
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| C0034 | France | ➤ Try a Free Trial | PRODUCT NAME: SORAFENIB TOSYLATE, ET AUTRES SELS PHARMACEUTIQUEMENT ACCEPTABLES DE SORAFENIB; REGISTRATION NO/DATE IN FRANCE: EU/1/06/342/001 DU 20060719; REGISTRATION NO/DATE AT EEC: EU/1/06/342/001 DU 20060719 |
| 2007 00002 | Denmark | ➤ Try a Free Trial | PRODUCT NAME: SORAFENIB TOSYLAT |
| 2006000059 | Germany | ➤ Try a Free Trial | PRODUCT NAME: SORAFENIB UND PHARMAZEUTISCH VERTRAEGLICHE SALZE DAVON; REGISTRATION NO/DATE: EU/1/06/342/001 20060719 |
| 2006008 | Lithuania | ➤ Try a Free Trial | PRODUCT NAME: SORAFENIBAS IR FARMACINIU POZIURIU PRIIMTINOS JO DRUSKOS; REGISTRATION NO/DATE: EU/1/06/342/001 20060719 |
| C 031/2006 | Ireland | ➤ Try a Free Trial | SPC 031/2006: 20070528, EXPIRES: 20210718 |
| 2006 008, C 1140840 | Lithuania | ➤ Try a Free Trial | PRODUCT NAME: SORAFENIBAS IR FARMACINIU PO?I?RIU PRIIMTINOS JO DRUSKOS; REGISTRATION NO/DATE: EU/1/06/342/001 20060719 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
For more information try a trial or see the plans and pricing
Serving hundreds of leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright 2002-2019 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
Major Patent Expirations 2019 - 2020
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
Major Patent Expirations 2019 - 2020
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2019, www.DrugPatentWatch.com.
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2019, www.DrugPatentWatch.com.
Follow DrugPatentWatch: